NewsBenzingaBioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed Benzinga 2026.09.30 20:22 (GMT+0) Open on Benzinga Other news If Apple Cuts iPhone Units in 2027, This Stock Could Be a Big Loser Trust company AnchorWatch Trust Company launches Bitcoin custody service Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today
